van Baal WM, Kenemans P, van der Mooren MJ.
et al. Increased C-reactive protein levels during short-term hormone replacement
therapy in healthy postmenopausal women. Thromb Haemost.1999;81:925-928.
Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive
Cushman M, Legault C, Barrett-Connor E.
et al. Effect of postmenopausal hormones on inflammation-sensitive proteins:
the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation.1999;100:717-722.
Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT
nested case-control study. Am J Epidemiol.1996;144:537-547.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently
healthy men. N Engl J Med.1997;336:973-979.
Tracy RP, Lemaitre RN, Psaty BM.
et al. Relationship of C-reactive protein to risk of cardiovascular disease
in the elderly. Arterioscler Thromb Vasc Biol.1997;17:1121-1127.
Koenig W, Sund M, Frohlich M.
et al. C-reactive protein, a sensitive marker of inflammation, predicts future
risk of coronary heart disease in initially healthy middle-aged men: results
from the MONICA Augsburg Cohort Study, 1984 to 1992. Circulation.1999;99:237-242.
Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. JAMA.2001;285:2481-2485.
Danesh J, Whincup P, Walker M.
et al. Low grade inflammation and coronary heart disease. BMJ.2000;321:199-204.
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction
of cardiovascular disease in women. N Engl J Med.2000;342:836-843.
Hulley S, Grady D, Bush T.
et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research
Group. Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women. JAMA.1998;280:605-613.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal
The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease
risk factors in postmenopausal women. JAMA.1995;273:199-208.
The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational
study. Control Clin Trials.1998;19:61-109.
Hastie T, Tibshirani R. Generalized Additive Models. London, England: Chapman & Hall/CRC; 1990.
Mohamed-Ali V, Goodrick S, Rawesh A.
et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis
factor-alpha, in vivo. J Clin Endocrinol Metab.1997;82:4196-4200.
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects. Arterioscler Thromb Vasc Biol.1999;19:972-978.
Hak AE, Stehouwer CD, Bots ML.
et al. Associations of C-reactive protein with measures of obesity, insulin
resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol.1999;19:1986-1991.
Rexrode KM, Manson JE, Hennekens CH. Obesity and cardiovascular disease. Curr Opin Cardiol.1996;11:490-495.
Weinhold B, Ruther U. Interleukin-6-dependent and -independent regulation of the human C-reactive
protein gene. Biochem J.1997;327:425-429.
Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB.for the European Concerted Action on Thrombosis and Disabilities Angina
Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable
and unstable angina. Lancet.1997;349:462-466.
Liuzzo G, Biasucci LM, Gallimore JR.
et al. The prognostic value of C-reactive protein and serum amyloid a protein
in severe unstable angina. N Engl J Med.1994;331:417-424.
Morrow DA, Rifai N, Antman EM.
et al. C-reactive protein is a potent predictor of mortality independently
of and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol.1998;31:1460-1465.
Biasucci LM, Liuzzo G, Grillo RL.
et al. Elevated levels of C-reactive protein at discharge in patients with
unstable angina predict recurrent instability. Circulation.1999;99:855-860.
Lindahl B, Toss H, Siegbahn A.
et al. Markers of myocardial damage and inflammation in relation to long-term
mortality in unstable coronary artery disease: FRISC Study Group. N Engl J Med.2000;343:1139-1147.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial
infarction among apparently healthy men. Circulation.2000;101:1767-1772.
Harris TB, Ferrucci L, Tracy RP.
et al. Associations of elevated interleukin-6 and C-reactive protein levels
with mortality in the elderly. Am J Med.1999;106:506-512.
Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and
Cushman M, Meilahn EN, Psaty BM.
et al. Hormone replacement therapy, inflammation, and hemostasis in elderly
women. Arterioscler Thromb Vasc Biol.1999;19:893-899.
Barinas-Mitchell E, Cushman M, Meilahn EN, Tracy RP, Kuller LH. Serum levels of C-reactive protein are associated with obesity, weight
gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol.2001;153:1094-1101.
Walsh BW, Paul S, Wild RA.
et al. The effects of hormone replacement therapy and raloxifene on C-reactive
protein and homocysteine in healthy postmenopausal women: a randomized, controlled
trial. J Clin Endocrinol Metab.2000;85:214-218.
Straub RH, Hense HW, Andus T.
et al. Hormone replacement therapy and interrelation between serum interleukin-6
and body mass index in postmenopausal women. J Clin Endocrinol Metab.2000;85:1340-1344.
Sattar N, Perera M, Small M, Lumsden MA. Hormone replacement therapy and sensitive C-reactive protein concentrations
in women with type-2 diabetes. Lancet.1999;354:487-488.
Lowe GD, Upton MN, Rumley A.
et al. Different effects of oral and transdermal hormone replacement therapies
on factor IX, APC resistance, t-PA, PAI and C-reactive protein. Thromb Haemost.2001;86:550-556.
Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue
factor induction by C-reactive protein. Circulation.2000;101:1785-1791.
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E.for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive
Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity
C-reactive protein measurements in healthy adults. Clin Chem.2001;47:444-450.
Ridker PM, Rifai N, Clearfield M.
et al. Measurement of C-reactive protein for the targeting of statin therapy
in the primary prevention of acute coronary events. N Engl J Med.2001;344:1959-1965.